Skip to main content

Table 3 Correlation of FGF-23 with categorical characteristics

From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Items FGF-23 (pg/mL), median (IQR) P value
Gender   0.946
 No 736.6 (634.3–808.5)  
 Yes 736.5 (608.0–905.8)  
Current smoke   0.700
 No 727.9 (608.2–907.5)  
 Yes 752.0 (661.8–855.1)  
Hypertension   0.167
 No 706.2 (571.8–887.1)  
 Yes 748.1 (641.0–886.0)  
Diabetes mellitus   0.201
 No 720.9 (587.0–862.8)  
 Yes 749.6 (657.8–907.5)  
Hypercholesteremia   < 0.001
 No 582.7 (482.5–694.4)  
 Yes 798.6 (720.0–988.4)  
Hyperuricemia   0.022
 No 715.8 (575.8–901.7)  
 Yes 766.4 (672.5–870.8)  
Family history of CAD   0.022
 No 729.5 (603.5–848.3)  
 Yes 781.4 (667.5–1005.0)  
Multivessel artery lesions   0.061
 No 691.2 (579.7–795.2)  
 Yes 750.2 (630.4–914.6)  
Patients with two target lesions   0.880
 No 746.5 (630.4–876.7)  
 Yes 721.2 (581.9–892.1)  
Target lesion at LAD   0.628
 No 720.3 (622.4–909.9)  
 Yes 748.9 (603.7–876.9)  
Target lesion at LCX   0.496
 No 741.1 (609.5–896.5)  
 Yes 734.3 (616.5–886.0)  
Target lesion at RCA   0.306
 No 749.6 (636.5–863.3)  
 Yes 698.1 (592.8–912.3)  
  1. Boldface represented P < 0.05
  2. FGF-23 fibroblast growth factor 23, IQR interquartile range, CAD coronary artery disease, LAD left anterior descending branch, LCX left circumflex artery, RCA right coronary artery